All In Biotech

Drug Trial Radar · NCT02491060

A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris

A Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2-Arm, Parallel Group Comparison Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris

Last checked: Nov 19, 2026Latest source record: Sep 14, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 800 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

800

Planned (sponsor's estimate)

Start

Sep 2015

Primary completion

Jul 2016

Study completion Jul 2016

Sponsor

Lead sponsor
Valeant PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Jul 7, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 9 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to compare the efficacy, safety and tolerability of IDP-121 Lotion and vehicle in the treatment of subjects with acne vulgaris.

Conditions

  • Acne Vulgaris

Interventions

  • IDP-121 LotionDrug

    Investigational Product: IDP-121 Lotion

  • IDP-121 Vehicle LotionDrug

    Comparator Product: IDP-121 Vehicle Lotion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Absolute change in inflammatory lesion count from baseline to Week 12Time frame: 12 weeks
  2. Absolute change in non-inflammatory lesion count from baseline to Week 12Time frame: 12 weeks
  3. Proportion of subjects who have a least a 2 grade reduction at Week 12 from baseline in the Evaluator's Global Severity Score and were Clear or Almost ClearTime frame: 12 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.